KR20140058975A - Extraction method of artemisia annua having anti-breast cancer and anti-cervical cancer activities - Google Patents
Extraction method of artemisia annua having anti-breast cancer and anti-cervical cancer activities Download PDFInfo
- Publication number
- KR20140058975A KR20140058975A KR1020120125497A KR20120125497A KR20140058975A KR 20140058975 A KR20140058975 A KR 20140058975A KR 1020120125497 A KR1020120125497 A KR 1020120125497A KR 20120125497 A KR20120125497 A KR 20120125497A KR 20140058975 A KR20140058975 A KR 20140058975A
- Authority
- KR
- South Korea
- Prior art keywords
- breast cancer
- cervical cancer
- extract
- present
- cancer
- Prior art date
Links
- 206010006187 Breast cancer Diseases 0.000 title claims abstract description 29
- 208000026310 Breast neoplasm Diseases 0.000 title claims abstract description 29
- 206010008342 Cervix carcinoma Diseases 0.000 title claims abstract description 29
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 title claims abstract description 29
- 201000010881 cervical cancer Diseases 0.000 title claims abstract description 29
- 230000000694 effects Effects 0.000 title claims abstract description 17
- 238000000605 extraction Methods 0.000 title claims abstract description 15
- 240000000011 Artemisia annua Species 0.000 title abstract description 5
- 235000001405 Artemisia annua Nutrition 0.000 title abstract description 5
- 239000000284 extract Substances 0.000 claims abstract description 36
- 239000000203 mixture Substances 0.000 claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 7
- 235000014375 Curcuma Nutrition 0.000 claims abstract description 3
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims abstract description 3
- 240000006891 Artemisia vulgaris Species 0.000 claims description 15
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 235000013376 functional food Nutrition 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 241000186216 Corynebacterium Species 0.000 claims 2
- 244000164439 Curcuma angustifolia Species 0.000 claims 1
- 244000019459 Cynara cardunculus Species 0.000 claims 1
- 235000019106 Cynara scolymus Nutrition 0.000 claims 1
- 240000000249 Morus alba Species 0.000 claims 1
- 235000008708 Morus alba Nutrition 0.000 claims 1
- 235000016520 artichoke thistle Nutrition 0.000 claims 1
- 235000013305 food Nutrition 0.000 abstract description 3
- 235000013336 milk Nutrition 0.000 abstract description 3
- 239000008267 milk Substances 0.000 abstract description 3
- 210000004080 milk Anatomy 0.000 abstract description 3
- 244000164480 Curcuma aromatica Species 0.000 abstract 1
- 239000000469 ethanolic extract Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 description 4
- 229960004191 artemisinin Drugs 0.000 description 4
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 description 3
- 235000003097 Artemisia absinthium Nutrition 0.000 description 3
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000001138 artemisia absinthium Substances 0.000 description 3
- 229930101531 artemisinin Natural products 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 210000000232 gallbladder Anatomy 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- PLQMEXSCSAIXGB-SAXRGWBVSA-N (+)-artemisinic acid Chemical compound C1=C(C)CC[C@H]2[C@H](C)CC[C@@H](C(=C)C(O)=O)[C@H]21 PLQMEXSCSAIXGB-SAXRGWBVSA-N 0.000 description 2
- VWGPQZZLIAQJCE-DWIPZSBTSA-N (1R,4S,5S,8R,9S,12R,14R)-4,8,12-trimethyl-2,13-dioxatetracyclo[7.5.0.01,5.012,14]tetradecan-3-one Chemical compound C([C@H]1[C@H](C)CC2)C[C@@]3(C)O[C@H]3[C@@]31[C@@H]2[C@H](C)C(=O)O3 VWGPQZZLIAQJCE-DWIPZSBTSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- LVJJFMLUMNSUFN-UHFFFAOYSA-N gallocatechin gallate Natural products C1=C(O)C=C2OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C1OC(=O)C1=CC(O)=C(O)C(O)=C1 LVJJFMLUMNSUFN-UHFFFAOYSA-N 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 2
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- LSHVYAFMTMFKBA-PZJWPPBQSA-N (+)-catechin-3-O-gallate Chemical compound O([C@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-PZJWPPBQSA-N 0.000 description 1
- WMBWREPUVVBILR-GHTZIAJQSA-N (+)-gallocatechin gallate Chemical compound O([C@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-GHTZIAJQSA-N 0.000 description 1
- LSHVYAFMTMFKBA-TZIWHRDSSA-N (-)-epicatechin-3-O-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-TZIWHRDSSA-N 0.000 description 1
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 1
- PJCCSJGLHBNKPR-GGXXFGPKSA-N (3aS,6aS,10aS)-10-hydroxy-3,6-dimethyl-9-methylidene-3a,4,5,6,6a,7,8,10-octahydro-3H-benzo[h][1]benzofuran-2-one Chemical compound CC1[C@@H]2CCC(C)[C@@H]3CCC(=C)C(O)[C@@]23OC1=O PJCCSJGLHBNKPR-GGXXFGPKSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
- KPCRYSMUMBNTCK-UHFFFAOYSA-N 3',5-dihydroxy-3,4',7-trimethoxyflavone Chemical compound C=1C(OC)=CC(O)=C(C(C=2OC)=O)C=1OC=2C1=CC=C(OC)C(O)=C1 KPCRYSMUMBNTCK-UHFFFAOYSA-N 0.000 description 1
- USMNOWBWPHYOEA-UHFFFAOYSA-N 3‐isothujone Chemical compound CC1C(=O)CC2(C(C)C)C1C2 USMNOWBWPHYOEA-UHFFFAOYSA-N 0.000 description 1
- 235000003129 Ambrosia artemisiifolia var elatior Nutrition 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 244000281762 Chenopodium ambrosioides Species 0.000 description 1
- 241001414720 Cicadellidae Species 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- 240000005109 Cryptomeria japonica Species 0.000 description 1
- 244000163122 Curcuma domestica Species 0.000 description 1
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 1
- LSHVYAFMTMFKBA-UHFFFAOYSA-N ECG Natural products C=1C=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 description 1
- PSMFFFUWSMZAPB-UHFFFAOYSA-N Eukalyptol Natural products C1CC2CCC1(C)COCC2(C)C PSMFFFUWSMZAPB-UHFFFAOYSA-N 0.000 description 1
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- FRUVDMZCZGVCDC-ASBIXWSPSA-N alpha-Epoxy-dihydroartemisinic acid Natural products O=C(O)[C@@H](C)[C@H]1[C@H]2[C@H]3[C@](C)(O3)CC[C@H]2[C@H](C)CC1 FRUVDMZCZGVCDC-ASBIXWSPSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 235000003484 annual ragweed Nutrition 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 229930191701 arteannuin Natural products 0.000 description 1
- PJCCSJGLHBNKPR-UHFFFAOYSA-N arteannuin L Natural products C1CC(C)C2CCC(=C)C(O)C32C1C(C)C(=O)O3 PJCCSJGLHBNKPR-UHFFFAOYSA-N 0.000 description 1
- QWQSMEDUZQDVLA-KPHNHPKPSA-N arteannuin b Chemical compound C([C@@]1(C)O[C@H]11)C[C@H]2[C@H](C)CC[C@@H]3[C@@]12OC(=O)C3=C QWQSMEDUZQDVLA-KPHNHPKPSA-N 0.000 description 1
- DMAQAYJMMDODRC-UHFFFAOYSA-N arteannuin-B Natural products CC1CCC2C(=C)COC23C1CCC4(C)OC34 DMAQAYJMMDODRC-UHFFFAOYSA-N 0.000 description 1
- PLQMEXSCSAIXGB-UHFFFAOYSA-N artemisininic acid Natural products C1=C(C)CCC2C(C)CCC(C(=C)C(O)=O)C21 PLQMEXSCSAIXGB-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000006263 bur ragweed Nutrition 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- RFFOTVCVTJUTAD-UHFFFAOYSA-N cineole Natural products C1CC2(C)CCC1(C(C)C)O2 RFFOTVCVTJUTAD-UHFFFAOYSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000003488 common ragweed Nutrition 0.000 description 1
- 235000019784 crude fat Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- FRUVDMZCZGVCDC-UHFFFAOYSA-N dihydro-alpha-epoxy-artemisinic acid Natural products C1CC2(C)OC2C2C(C(C)C(O)=O)CCC(C)C21 FRUVDMZCZGVCDC-UHFFFAOYSA-N 0.000 description 1
- JYGAZEJXUVDYHI-DGTMBMJNSA-N dihydroartemisinic acid Chemical compound C1CC(C)=C[C@@H]2[C@H]([C@@H](C)C(O)=O)CC[C@@H](C)[C@@H]21 JYGAZEJXUVDYHI-DGTMBMJNSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 1
- 150000002216 flavonol derivatives Chemical class 0.000 description 1
- 235000011957 flavonols Nutrition 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 235000008777 kaempferol Nutrition 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229930007744 linalool Natural products 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 235000009736 ragweed Nutrition 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930004725 sesquiterpene Natural products 0.000 description 1
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 229930007110 thujone Natural products 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- -1 ρ-cymene Chemical compound 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
Abstract
The present invention relates to a method for extracting artemisia annua L, which is optimized for anti-breast cancer and anti-cervical cancer activity. The present invention also provides a milk curcuma extract having anti-breast cancer and anti-cervical cancer activity extracted according to the above extraction method, and an anti-breast cancer and anti-cervical cancer pharmaceutical composition or food composition containing the same.
Description
The present invention relates to a method for extracting artemisia annua L, which is optimized for anti-breast cancer and anti-cervical cancer activity. The present invention also relates to a rabbit extract having anti-breast cancer and anti-cervical cancer activity extracted according to the above extraction method, and an anti-breast cancer and anti-cervical cancer pharmaceutical composition or food composition containing the same.
It is a perennial plant belonging to Asteraceae and distributed in Korea, Japan, Taiwan, Mongolia and Siberia. It is also called Leaf wormwood, Leaf wormwood.
It is about 1m in height, growing in Gilgana, Vinter, and riverside. It is broadly distributed in Korea, Jeju, Pyongbuk, Hamam, Asia and Europe. In China, it has long been used as a medicinal herb for the treatment of malaria. Artemisinin, a major component of sesquiterpene, is now being used as a medicinal product because of its potent anti-malarial efficacy. It is known that linalool, 1,8-cineol, ρ-cymene, thujone and camphor are present as essential oil components of mugwort.
Artemisinin, arteannuin B, artemisininic acid, dihydroartmisinic acid, and the like are included in the artemisia annua, Alpha-epoxydihydroartemisinic acid, Arteannuin L, Arteannuin N, Dihydroarteannuin B, 3, < RTI ID = 0.0 & 3 ', 7-trimethylquercetin, 3,4', 7-trimethylquercetin, which is resistant to the resistance of malaria pathogens to cryptomeria And artemisinin, which has high efficacy. However, there are almost no studies on the artificial insect wormwood in Korea.
Accordingly, the technical problem to be solved by the present invention is to provide a method for extracting dog gallmops, which is optimized for anti-breast cancer and anti-cervical cancer activity.
Another technical problem to be solved by the present invention is to provide a ragweed extract having anti-breast cancer and anti-cervical cancer activity extracted according to the above-mentioned method for extracting dog mugwort.
Another object of the present invention is to provide an anti-breast cancer and anti-cervical cancer pharmaceutical composition and a food composition containing the milk curd extract.
In order to accomplish the above object, the present invention provides a method for extracting dog gallstone having an anti-breast cancer and anti-cervical cancer activity, which comprises extracting an aqueous ethanol solution of 70 to 90 vol% do.
Preferably, the mugwort used in the method for extracting mugwort is the mugwort mugwort.
Preferably, the concentration of ethanol in the ethanol aqueous solution used as the extraction solvent used in the method of the present invention is 70 to 80% by volume, more preferably 80% by volume.
The content of moisture, crude lipid and crude lipid in the extract of the present invention is high, and the content of ash, crude fiber and mineral is high in the extract of D. mugwort. Total phenol and flavonoid contents were about twice as high as leaf extracts.
The present invention also provides a rabbit extract having anti-breast cancer and anti-cervical cancer activity extracted according to the above extraction method.
Preferably, the effective concentration of the rabbit extract of the present invention is in the range of 10 to 10,000 占 퐂 / ml, more preferably 100 to 1,000 占 퐂 / ml, and still more preferably 200 to 500 占 퐂 / ml.
The present invention provides an anti-breast cancer and anti-cervical cancer pharmaceutical composition or a functional food composition containing the rabbit extract as an active ingredient.
The functional food which can be used in the present invention is, for example, beverage, gum, tea, vitamin complex, health supplement, bread, confectionery, candy and the like. But is not limited thereto.
That is, the anti-breast cancer and anti-cervical cancer compositions prepared according to the extraction method of the present invention can be produced in the form of medicines and functional foods. Such medicaments and functional foods may include pharmaceutically acceptable excipients or additives. The compositions of the present invention may be administered alone or in admixture with any convenient vehicle, excipient, or the like, and such dosage forms may be single-dose or multiple-dose formulations.
The pharmaceutical or functional food containing the composition of the present invention may be a solid preparation or a liquid preparation. Solid preparations include, but are not limited to, powders, granules, tablets, capsules, suppositories, and the like. Solid form preparations may include, but are not limited to, excipients, flavoring agents, binders, preservatives, disintegrants, lubricants, fillers, and the like. Examples of the liquid preparation include water, a solution such as a solution of propylene glycol, a suspension, an emulsion, and the like, but not limited thereto, and it can be prepared by adding a suitable coloring agent, a flavoring agent, a stabilizer, a tackifying agent and the like.
For example, the acid can be prepared by simple mixing of a dog milk mugwort extract prepared under a specific extraction condition, which is an effective ingredient of the present invention, and a pharmaceutically acceptable excipient such as lactose, starch and microcrystalline cellulose. The granules may be selected from the group consisting of the rabbit extract of the present invention; Suitable excipients which are pharmaceutically acceptable; And a suitable pharmaceutically acceptable binder such as polyvinylpyrrolidone and hydroxypropylcellulose, followed by wet granulation using a solvent such as water, ethanol or isopropanol or dry granulation using a compressive force . Further, the tablet may be prepared by mixing the above granule with a suitable pharmaceutically acceptable salt such as magnesium stearate and then tableting it using a tablet machine.
The composition of the present invention may be administered orally or parenterally (for example, intramuscular injection, intraperitoneal injection, intravenous injection, infusion, subcutaneous injection, implant), inhalant, nasal administration agent, , Rectal, sublingual, transdermal, topical, and the like, but is not limited thereto. May be formulated into suitable dosage unit formulations, including those conventionally used and non-toxic, pharmaceutically acceptable carriers, additives, vehicles according to the route of administration. Depot formulations that are capable of sustained release of the drug over a period of time are also within the scope of the present invention.
In order to achieve the object of the present invention, the anti-breast cancer and anti-cervical cancer activity, the crude guarwood extract prepared according to the method of the present invention may be administered at about 0.0001 mg / kg to about 10 g / kg daily, kg to about 1 < RTI ID = 0.0 > g / kg. < / RTI > However, the above dosage may vary depending on the degree of purification of the dog gall bladder extract, the condition of the patient (age, sex, weight, etc.), severity of the condition being treated, and the like. For convenience, the total daily dose may be divided as needed and divided into several doses throughout the day.
The present invention provides a method for producing Lauroginae Extract having anti-breast cancer and anti-cervical cancer activity. These extracts exhibit a high proliferation inhibitory activity on human breast cancer cell MCF-7 and cervical cancer cell HeLa cells. Also, the present invention provides an anti-breast cancer and anti-cervical cancer pharmaceutical composition or a functional food composition containing an anti-breast cancer and an anti-cervical cancer extract extracted according to the above extraction method and an anti-cow cancer extract containing the anti-cow cancer extract as an active ingredient .
Hereinafter, production examples and examples will be described in detail to facilitate understanding of the present invention. However, the production examples and examples according to the present invention can be modified into various other forms, and the scope of the present invention should not be construed as being limited to the following production examples and examples. The production examples and embodiments of the present invention are provided to enable those skilled in the art to more fully understand the present invention.
< Example 1> Preparation of Mugwort Extract
Leaf and stem were extracted from water and 80 vol% ethanol aqueous solution.
The contents of moisture, crude fat and crude protein were higher in leaf extracts, but ash and crude fiber contents were significantly higher in stem.
In mineral extracts, 9 species were detected from leaf extracts and 6 species from stem extracts. The contents of K and Ca were the most abundant. The constituent amino acids were 2356.10 mg% in the leaves and 996.34 mg% in the stems. The leaves were about twice as high and glutamic acid was the most abundant.
The free amino acid content was similar to the constituent amino acid content and was about 1.4 times higher in the leaves and the proline content was the highest, accounting for more than 50% of the total amino acids.
The total phenol contents of water extracts and ethanol extracts were 88.19 mg / g and 99.98 mg / g in leaf water and ethanol extracts, respectively, and 45.03 mg / g and 41.44 mg / g, about twice as high as the stem. The content of flavonoids was similar to total phenol content, and the highest value was 51.86 mg / g in ethanol extract of leaves.
As a result of analysis of the components of each extract by HPLC, phenolic acid was identified 10 species and 9 species respectively in the water and ethanol extracts of the gall bladder leaves, and water and ethanol extracts of the gall bladder stem were 8 Species and 6 species were identified.
Flavonols were identified only from the leafhopper leaf extract, and rutin and kaempferol were identified only from the leaf ethanol extract. The contents of catechin, gallocatechin gallate, epicatechin gallate and catechin gallate were significantly higher in the ethanol extract of the leaves than in the stem.
< Test Example 1> Anti-breast cancer And Anti-cervical cancer Active measurement
The proliferation inhibitory activity of MCF-7, which is a human breast cancer cell, and HeLa, a cervical cancer cell, was measured for each of the mugwort extracts obtained in Example 1 above.
As a result, the cancer cell proliferation inhibitory activity was significantly elevated with increasing concentration of the mugwort extract. Especially, the activity of ethanol extract was higher than that of leaf extract and water extract.
The inhibitory activity of the ethanol extracts of P. aeruginosa leaf on MCF - 7 and HeLa cells was 76.26% and 54.59% at 250 ㎍ / ㎖, respectively.
In addition, the inhibitory activity against HeLa was as high as 61.07% at 500 ㎍ / ㎖ ethanol extract of.
The extraction conditions in the method of extracting dog mugwort of the present invention is an extraction method in which the effects of anti-breast cancer and anti-cervical cancer are optimized. The present invention provides an anti-breast cancer and anti-cervical cancer pharmaceutical composition or a functional food composition containing an extract of Curcuma larvae extracted as an active ingredient according to such an extraction method. The extract of P. japonica extract according to the present invention is expected to be useful in the art because it can greatly enhance anti-breast cancer and anti-cervical cancer activity.
Claims (6)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020120125497A KR20140058975A (en) | 2012-11-07 | 2012-11-07 | Extraction method of artemisia annua having anti-breast cancer and anti-cervical cancer activities |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020120125497A KR20140058975A (en) | 2012-11-07 | 2012-11-07 | Extraction method of artemisia annua having anti-breast cancer and anti-cervical cancer activities |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20140058975A true KR20140058975A (en) | 2014-05-15 |
Family
ID=50889021
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020120125497A KR20140058975A (en) | 2012-11-07 | 2012-11-07 | Extraction method of artemisia annua having anti-breast cancer and anti-cervical cancer activities |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20140058975A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180137231A (en) | 2017-06-16 | 2018-12-27 | 성균관대학교산학협력단 | Pharmaceutical composition for preventing and treating renal cell carcinoma comprising fraction and subfraction of Artemisia annua L. |
| KR20200072980A (en) | 2018-12-13 | 2020-06-23 | 박서영 | A method of extracting dogworms with excellent medicinal ingredients and a method of manufacturing health supplements that maximize taste and efficacy using dogworm extract |
| KR20220091245A (en) * | 2020-12-23 | 2022-06-30 | 주식회사 생활한방연구소 | Novel use of extract of Artemisia annua |
-
2012
- 2012-11-07 KR KR1020120125497A patent/KR20140058975A/en not_active Application Discontinuation
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180137231A (en) | 2017-06-16 | 2018-12-27 | 성균관대학교산학협력단 | Pharmaceutical composition for preventing and treating renal cell carcinoma comprising fraction and subfraction of Artemisia annua L. |
| KR20200072980A (en) | 2018-12-13 | 2020-06-23 | 박서영 | A method of extracting dogworms with excellent medicinal ingredients and a method of manufacturing health supplements that maximize taste and efficacy using dogworm extract |
| KR20220091245A (en) * | 2020-12-23 | 2022-06-30 | 주식회사 생활한방연구소 | Novel use of extract of Artemisia annua |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101952416B1 (en) | Compositions and methods for joint health | |
| KR101189191B1 (en) | Composition comprising longan arillus extract or mixed extracts comprising the same for neurodegenerative diseases | |
| US20180271924A1 (en) | Compound and method for reducing inflammation, pain, allergy, flu and cold symptoms | |
| ES2613381T3 (en) | New extracts of Cynara scolymus, Coffea spp. and Olea Europaea for the treatment of metabolic syndrome | |
| KR20160042017A (en) | Agent for promoting in vivo absorption of hydroxytyrosol and derivatives thereof and use of same | |
| KR101187032B1 (en) | Composition containing the extracts, fractions and gymnasterkoreayne B of Gymnaster koraiensis for the hepatoprotection | |
| KR101426356B1 (en) | Composition for preventing or treating retinal disease containing extracts of persimmon | |
| KR20140058975A (en) | Extraction method of artemisia annua having anti-breast cancer and anti-cervical cancer activities | |
| KR101917363B1 (en) | A pharmaceutical composition comprising extract from germinated gemmule of bean for preventing or treating menopausal disorder | |
| KR101964054B1 (en) | Pharmaceutical composition comprising extract of Lonicera japonica for prevention and treatment of Crohn's disease | |
| KR20120045591A (en) | Composition comprising an combined herb extract including rhei radix et rhizoma for treating or preventing cognitive dysfunction | |
| KR101345653B1 (en) | Compositions Comprising Sophora Subprostrata Extracts for Inhibiting the Activity of Acetylcholinesterase | |
| KR100830553B1 (en) | Composition comprising the mixed extract of aralia cordata thunb. and cimicifuga heracleifolia kom. for preventing and treating inflammatory disease | |
| MXPA05002081A (en) | Psidium guajava improved extracts, methods for obtaining and using the same in the treatment of gastrointestinal diseases. | |
| KR101413771B1 (en) | A composition for anti-obesity comprising extract of big cone pine needle | |
| KR101332824B1 (en) | Pharmaceutical Compositions for Preventing or Treating Arthritis Comprising Euphorbia ebracteolata Extracts | |
| KR101423875B1 (en) | A composition comprising the complex extract for preventing or treating stroke and degenerative brain disease | |
| KR101194974B1 (en) | A composition comprising the extract of Crataegus pinnatifida treating and preventing neuro-degenerative disease | |
| KR20080088163A (en) | Pharmaceutical composition comprising the fractions of root of polygonum cuspidatum for neuroprotective effect | |
| KR100571851B1 (en) | Pharmaceutical composition comprising the low alcohol soluble extract or the essential oil fraction isolated from angelica acutloba for the prevention and treatment of nicotine addition and withdrawal symptoms | |
| KR20150127808A (en) | A pharmaceutical composition for treating and preventing liver demage and a functional food for protecting liver comprising the soybean sprout extract by high hydrostatic pressure | |
| KR102001338B1 (en) | Pharmaceutical Composition comprising the Extracts of Mixed Crude Drugs for the Prevention or Treatment of the Parkinson's Disease | |
| KR102381447B1 (en) | Pharmaceutical composition comprising the flower extract of camellia japonica as an effective component for prevention or treatment of thrombosis and health functional food comprising the same | |
| KR101348471B1 (en) | A composition comprising Larrea cuneifolia Cav. for the prevention and treatment of menopausal symptom | |
| KR101533487B1 (en) | Anti-Inflammatory Composition and Anti-Urolithiasis Composition Comprising Extract from Quercus gilva Blume or Polyphenols Isolated from the Same As Active Ingredient |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WITN | Withdrawal due to no request for examination |